Trials / Terminated
TerminatedNCT00243204
Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Point Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 3 study will compare the efficacy of talabostat plus docetaxel to docetaxel plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | talabostat mesylate | |
| DRUG | docetaxel |
Timeline
- Start date
- 2006-01-01
- First posted
- 2005-10-21
- Last updated
- 2007-06-08
Locations
96 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00243204. Inclusion in this directory is not an endorsement.